Trials / Unknown
UnknownNCT04683770
Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer
An Observational Study：Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Our study is aimed to explore a prospective observational clinical study on the efficacy prediction and survival prediction of HR + / HER2 - biomarkers detection in patients with advanced breast cancer. This study is a prospective, observational clinical study. We analyzed the incidence of biomarker mutations in HR + / HER2 - advanced breast cancer (stage IV), and the correlation between biomarkers and therapeutic efficacy, survival, and prognosis.
Conditions
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2021-07-01
- Completion
- 2022-07-01
- First posted
- 2020-12-24
- Last updated
- 2020-12-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04683770. Inclusion in this directory is not an endorsement.